Skip to main content
Equibles
PIII logo

PIII · P3 Health Partners Inc.

Track PIII — free

Use PIII with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PIII

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.69 -0.27 (-2.46%) At close · Aug 14
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these matters, substantial doubt exists about the Company's ability to continue as a going concern for one year after the date the financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$84.88M
Shares
7.26M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.69 Open$10.81 Day$10.63–11.10 52W close$1.52–16.47 Avg vol 30d53K Short int36K · 0.5% float · 1.7d Short vol75% Last earningsAug 10, 2026 DataApr 2025–Aug 2026 Filing10-Q · Aug 10

Raw chart and full-history price indicators begin at the captured split on Apr 14, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 8, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +74%
      above
      Price vs 50-day avg −3%
      below
      RSI (14) 49
      neutral
      MACD trend Positive
      52-week position 61%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return −1%
      trailing
      6-month return +402%
      trailing
      YTD return +206%
      this year
      Relative strength +388%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $6 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +10 funds added
      Insider flow Distributing
      Net -$823.9K over 90 days · 100% sells
      Short interest Falling
      0.50% of float · ▼ -6.1% MoM · 1.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      33 holders — mid 3-yr range
      Squeeze score 43
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −3%
      Y/Y
      EPS growth +16%
      Y/Y
      Free cash flow $-91.2M
      Balance sheet $248.4M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 219%
      annualized · 1-yr
      Max drawdown −85%
      past year
      ATR 10.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 10, 2026
      Total Revenues · Year Ending December 31, 2026 $1.5B – $1.6B
      Medical Margin · Year Ending December 31, 2026 Non-GAAP $260M – $300M
      Medical Margin PMPM · Year Ending December 31, 2026 Non-GAAP $210 – $240
      Adjusted EBITDA · Year Ending December 31, 2026 Non-GAAP $80M – $110M
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
      Adjusted EBITDA · full year 2025 $-110M – $-95M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +74% Bullish
      Price vs 50-day avg
      −3% Neutral
      RSI (14)
      49 Neutral
      MACD trend
      Positive Bullish
      52-week position
      61% Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $6 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +10 funds added
      Insider flow Distributing
      Net -$823.9K over 90 days · 100% sells
      Short interest Falling
      0.50% of float · ▼ -6.1% MoM · 1.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      33 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $2 Now $11 · 61% Range high $16
      vs 200-day avg +74% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      average number of at-risk members 104,800 the three months ended June 30, 2026 filing —
      Medical margin (excluding payer settlements and prior year development) non-GAAP $52.9M Q2 2026 —
      Medical margin PMPM non-GAAP $311 Q2 2026 —
      Medical margin PMPM (excluding payer settlements and prior year development) non-GAAP $168 Q2 2026 —
      Platform support costs 26.97M Three Months Ended June 30, 2026 filing —
      Platform support costs as % of total operating revenue 7% Three Months Ended June 30, 2026 filing —
      Medical margin (excluding prior year development and payer settlements) non-GAAP $56.1M first quarter 2026 —
      Medical margin per-member non-GAAP $231 first quarter 2026 —
      Capitated revenue PMPM $1,026 Full Year 2025 —
      Normalized Adjusted EBITDA non-GAAP -$149.1M Full Year 2025 —
      Normalized medical margin non-GAAP $53.4M Full Year 2025 —
      Normalized medical margin PMPM non-GAAP $38 Full Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PIII
      P3 Health Partners Inc.
      this stock
      		$84.88M +206.2% -2.8% — 0.5%
      HCA
      HCA Healthcare, Inc.
      		 $89.77B -13.3% +7.1% 13.9 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.87B -4.4% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $21.48B +34.8% +0.9% 10.3 4.0%
      FMS
      Fresenius Medical Care AG
      		 $12.65B -0.2% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      33
      % held
      51.1%
      Net QoQ
      -3.3M sh
      Top holder
      LMR Partners LLP
      Held Float
      View
      Held by Funds
      Fund positions
      11
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      36.0K
      Days to cover
      1.7d
      Change
      -2.3K sh
      View
      Short Volume
      Short vol %
      75%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      60
      Value
      $605
      As of
      Jul 9, 2026
      View
      Off-Exchange
      Off-exchange %
      40.4%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$823.9K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.5B
      Net income (FY)
      $-147.9M
      EPS diluted
      $-45.26
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 10, 2026
      This year
      14
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 10, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Apr 14, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      PIII -7.7% -1.3% +401.6% +8.7% +206.2%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -8.1% -5.7% +387.9% +4.8% +192.3%
      Key facts CIK 1832511 CUSIP 744413204 13F (30d) 34 filings 34 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)